Skip to main content
. 2013 Jan 21;10(3):243–249. doi: 10.7150/ijms.3971

Table 2.

Changes in BCVA and CMT of each group.

Baseline CMT 250μm-300μm 300μm - 500μm
Natural course (n=28) Natural course (n=17) IVTA (n=15) Laser (n=16) p-value*
BCVA (logMAR) p-value p-value p-value p-value
Baseline 0.32±0.27 0.61±0.41 0.71±0.45 0.58±0.36 0.643
1 month 0.35±0.34 0.741 0.62±0.38 0.906 0.48±0.28 0.097 0.55±0.38 0.817 0.508
3 months 0.30±0.24 0.713 0.59±0.56 0.924 0.48±0.24 0.089 0.59±0.35 0.937 0.691
6 months 0.28±0.24 0.533 0.55±0.53 0.718 0.52±0.36 0.218 0.67±0.45 0.556 0.649
CMT (μm)
Baseline 274.14±16.95 374.94±62.03 416.80±38.00 378.00±53.62 0.058
1 month 287.54±47.92 0.172 318.88±82.17 0.032 290.40±70.48 0.000 307.31±93.76 0.014 0.627
3 months 296.79±79.10 0.149 304.00±65.09 0.003 275.40±93.24 0.000 297.00±113.86 0.018 0.668
6 months 283.75±69.03 0.480 284.18±80.84 0.001 310.33±103.28 0.002 285.69±115.76 0.009 0.720

IVTA: intravitreal injection of triamcinolone acetonide; BCVA: best corrected visual acuity; CMT: central macular thickness

*Kruskal-Wallis test (p<0.05)

Wilcoxon Matched-Pairs Signed-Ranks test (p<0.05)

: baseline - 1 month, baseline - 3 months, baseline - 6 months